NCT02521181View on ClinicalTrials.gov

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

PHASE3CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

June 30, 2018

Conditions
Chronic Kidney Disease
Interventions
DRUG

Lower Dose Sodium Bicarbonate

Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)

DRUG

Higher Dose Sodium Bicarbonate

Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)

DRUG

Placebo

Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate

Trial Locations (7)

20037

George Washington University, Washington D.C.

60611

Northwestern University, Chicago

76502

Baylor/Scott & White, Temple

80230

Denver Nephrology Research, Denver

84112

University of Utah, Salt Lake City

Utah VA, Salt Lake City

44195-5196

Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue, Cleveland

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

The Cleveland Clinic

OTHER

lead

Jennifer Gassman, PhD

OTHER

NCT02521181 - The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR) | Biotech Hunter | Biotech Hunter